AstraZeneca Pharma India Ltd Q3 Results
- BSE: 506820
- NSE: ASTRAZEN
- ISIN: INE203A01020
- Sector: Biotechnology & Drugs
BSE
8,351.00
42.70 (0.51%)
42.70 (0.51%)Volume191.00
Updated: Wed 13 May, 2026 | 15:29:12
NSE
8,376.0056.00 (0.67%)
56.00 (0.67%)Volume5.59 K
Updated: Wed 13 May, 2026 | 15:29:56
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹611.57 Cr.(38.90%)
- Operating Profit₹42.47 Cr.(23.57%)
- Profit After Tax₹32.59 Cr.(5.64%)
- Operating Margin6.94%(-11.04%)
Note: Comparison is on YoY basis
Quarterly - AstraZeneca Pharma India Ltd Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 25 | QoQ Comp | Dec 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 569.10 | 491.77 | 15.72% | 405.92 | 40.20% |
| Depreciation/ Amortization | 3.84 | 2.57 | 49.42% | 9.07 | -57.66% |
| Operating Income | 42.47 | 67.32 | -36.91% | 34.37 | 23.57% |
| Net Income | 32.59 | 54.22 | -39.89% | 30.85 | 5.64% |
| Other Operating Expenses Total | 69.47 | 65.51 | 6.04% | 31.33 | 121.74% |
| Net Income Before Taxes | 46.54 | 72.82 | -36.09% | 42.02 | 10.76% |
| Total Revenue | 611.57 | 559.09 | 9.39% | 440.29 | 38.90% |
| Selling/ General/ Admin Expenses Total | 130.88 | 93.91 | 39.37% | 84.94 | 54.09% |
| Diluted Normalized EPS | 12.63 | 23.27 | -45.73% | 22.19 | -43.11% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.